Details
Stereochemistry | RACEMIC |
Molecular Formula | C16H26NO4S.C7H7O3S |
Molecular Weight | 499.641 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=C(C=C1)S([O-])(=O)=O.CCOCC(O)COC2=CC=C(NC(=O)CC[S+](C)C)C=C2
InChI
InChIKey=RYVJQEZJUFRANT-UHFFFAOYSA-N
InChI=1S/C16H25NO4S.C7H8O3S/c1-4-20-11-14(18)12-21-15-7-5-13(6-8-15)17-16(19)9-10-22(2)3;1-6-2-4-7(5-3-6)11(8,9)10/h5-8,14,18H,4,9-12H2,1-3H3;2-5H,1H3,(H,8,9,10)
Molecular Formula | C16H26NO4S |
Molecular Weight | 328.447 |
Charge | 1 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | C7H7O3S |
Molecular Weight | 171.194 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.jstage.jst.go.jp/article/allergolint/54/4/54_4_533/_pdf
Curator's Comment: Description was created based on several sources, including
https://www.jstage.jst.go.jp/article/allergolint/54/4/54_4_533/_pdf
Suplatast is a novel immunomodulator that can adjust the imbalance in the Th1/Th2 immune response and shows clear clinical efficacy against bronchial asthma (BA). Suplatast tosilate helps to suppress the production of IgE, to block the production of cytokines and to suppress allergy-related eosinophils. Clinical studies on the efficacy of Suplatast were carried out in Japan. Suplatast showed adequate efficacy for the treatment of BA, allergic rhinitis and atopic dermatitis. Suplatast is now available for the management of BA as a controller of the Th2-dependent allergic inflammation. Suplatast tosilate is not approved in the United States, but is available in Japan as Tosilart® and IPD Capsules®. IPD-1151T (suplatast tosilate) was originated by Taiho and is being developed for the treatment of interstitial cystitis and chronic non-bacterial prostatitis as additional indications. IPD-1151T treatment for 1 year resulted in a significantly increased bladder capacity and decreased symptoms, such as urinary urgency, frequency and lower abdominal pain, in patients with nonulcerative interstitial cystitis.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P05112 Gene ID: 3565.0 Gene Symbol: IL4 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/10466742 |
|||
Target ID: CHEMBL1169600 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10466742 |
|||
Target ID: CHEMBL3243911 Sources: http://www.ncbi.nlm.nih.gov/pubmed/19596986 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
|||
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9609984 |
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Suplatast tosilate affects the initial increase in specific IgE and interleukin-4 during immunotherapy for perennial allergic rhinitis. | 1998 |
|
Suplatast tosilate (IPD), a new immunoregulator, is effective in vitiligo treatment. | 1998 Apr |
|
Suplatast tosilate inhibits goblet-cell metaplasia of airway epithelium in sensitized mice. | 2000 Apr |
|
Kimura's disease treated with suplatast tosilate and loratadine. | 2011 Nov-Dec |
|
Treatment of non-episodic angioedema associated with eosinophilia with suplatast tosilate, an anti-allergic selective Th2 cytokine inhibitor. | 2014 Mar-Apr |
|
[A case report of eosinophilic cystitis treated with oral suplatast tosilate]. | 2014 Sep |
|
Suplatast tosilate for treating cutaneous mastocytosis. | 2015 May-Jun |
Patents
Sample Use Guides
IPD-1151T (suplatast tosilate) 100 mg capsules was orally administered to the patients 3 times daily for 12 weeks of treatment period.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/10756224
In vitro, NCI-H292 cells were preincubated with suplatast tosilate (0.1-100 u/mL) 1 hour.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 06:45:09 GMT 2023
by
admin
on
Sat Dec 16 06:45:09 GMT 2023
|
Record UNII |
C9J89787U1
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C574
Created by
admin on Sat Dec 16 06:45:09 GMT 2023 , Edited by admin on Sat Dec 16 06:45:09 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000082984
Created by
admin on Sat Dec 16 06:45:09 GMT 2023 , Edited by admin on Sat Dec 16 06:45:09 GMT 2023
|
PRIMARY | |||
|
m10402
Created by
admin on Sat Dec 16 06:45:09 GMT 2023 , Edited by admin on Sat Dec 16 06:45:09 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL1180156
Created by
admin on Sat Dec 16 06:45:09 GMT 2023 , Edited by admin on Sat Dec 16 06:45:09 GMT 2023
|
PRIMARY | |||
|
94055-76-2
Created by
admin on Sat Dec 16 06:45:09 GMT 2023 , Edited by admin on Sat Dec 16 06:45:09 GMT 2023
|
PRIMARY | |||
|
SUB10776MIG
Created by
admin on Sat Dec 16 06:45:09 GMT 2023 , Edited by admin on Sat Dec 16 06:45:09 GMT 2023
|
PRIMARY | |||
|
C073028
Created by
admin on Sat Dec 16 06:45:09 GMT 2023 , Edited by admin on Sat Dec 16 06:45:09 GMT 2023
|
PRIMARY | |||
|
DTXSID9045003
Created by
admin on Sat Dec 16 06:45:09 GMT 2023 , Edited by admin on Sat Dec 16 06:45:09 GMT 2023
|
PRIMARY | |||
|
C9J89787U1
Created by
admin on Sat Dec 16 06:45:09 GMT 2023 , Edited by admin on Sat Dec 16 06:45:09 GMT 2023
|
PRIMARY | |||
|
71773
Created by
admin on Sat Dec 16 06:45:09 GMT 2023 , Edited by admin on Sat Dec 16 06:45:09 GMT 2023
|
PRIMARY | |||
|
C152475
Created by
admin on Sat Dec 16 06:45:09 GMT 2023 , Edited by admin on Sat Dec 16 06:45:09 GMT 2023
|
PRIMARY | |||
|
6709
Created by
admin on Sat Dec 16 06:45:09 GMT 2023 , Edited by admin on Sat Dec 16 06:45:09 GMT 2023
|
PRIMARY | |||
|
SUPLATAST TOSILATE
Created by
admin on Sat Dec 16 06:45:09 GMT 2023 , Edited by admin on Sat Dec 16 06:45:09 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |